Compare State Street SPDR S&P Biotech ETF (XBI) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Financial Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.85, while Financial Select Sector SPDR Fund trades at $57.23. Which is the better fit depends on your goals.
| XBI | XLF | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $58.55 |
52-Week Low | $93.43 | $47.80 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XLF trades at $57.30, down 1.38% amid neutral technical signals with mixed moving averages and oscillators. The ETF consolidates near key support at $57 with resistance at $58. Recent news highlights fund manager rotation into financial stocks in Q2 2026 as rising rates benefit banks and insurers, though year-to-date performance remains modest.
Outlook hinges on interest rate trends favoring financials, with competitive expense ratios attracting investors. Risks include economic sensitivity and sector concentration. Wall Street sentiment is balanced with technical indicators suggesting near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
